AstraZeneca to present positive health economics data on Brilique/Brilinta at ISPOR meeting in November

AstraZeneca will present key results from health economics sub-studies from the PLATO trial at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) EU meeting, 5-8 November in Madrid. Data from eight countries will show that using Brilique/Brilinta plus aspirin to treat acute coronary syndrome patients for one year is associated with cost-savings, gain in quality-adjusted life years, and life-years gained compared to treatment with both generic and branded clopidogrel plus aspirin.see�Brilique health economics sub-studies for Brazil (abstract #33322), Canada (abstract #33335), Germany (abstract #32529), Greece (abstract #34099), Holland (abstract #32584), Mexico (abstract #33517), Poland (abstract #33653), and Spain (abstract #33160), to be presented Monday 7 November, 8:00-19:30